Blueprint still sees an oncology future
Despite a growing presence outside cancer, the company wants to stay true to its “DNA”.
Despite a growing presence outside cancer, the company wants to stay true to its “DNA”.
The group reports more data today, while its pivotal Ares trial, in acute graft-versus-host disease, is set to read out in the fourth quarter.
The company reckons its tech could solve problems with current ADCs, but the market isn’t giving it much credit yet.
For now, the group is sticking with what it knows ahead of a big year in lymphoma.
The company makes no secret of the need for durability with its anti-CD47 project SL-172154.
Five years after Affimed switched to NK cell engagers investors will see the fruits of a potentially registrational trial.
Can a combination approach improve the efficacy of ziftomenib in AML patients with KMT2A rearrangements?
As a key mid-stage readout approaches for the group’s neoantigen immunotherapy, Gritstone still has much to prove.
Rates of infection-related deaths continue to raise eyebrows, but the company has some potential explanations.
The group highlights safety and manufacturability, as well as efficacy, but investors apparently have doubts.